DBDrew H. Barzman

Drew H. Barzman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Drew H. Barzman has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Melissa P. DelBello

    Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio

    3 shared publications
  • Stephen M. Strakowski

    Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio

    3 shared publications
  • Ann-Marie Kahwaty

    Anchoring Families Together Crisis Stabilization Center, Cincinnati, United States

    1 shared publication
  • Beth Gernert

    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio

    1 shared publication
  • Brian J. McConville

    Department of Psychiatry, University of Cincinnati Medical Center, United States

    1 shared publication
  • Brian Masterson

    Department of Psychiatry, University of Cincinnati Medical Center, United States

    1 shared publication

Latest Publications

  • Pharmacological treatment of pathologic aggression in children

    by Drew H. Barzman, Robert L. Findling

    Children with psychiatric illness may display pathologic aggression (PA) that is destructive, severe, chronic, and unresponsive to psychosocial and psychopharmacological treatment of their underlying condition(s) and psychosocial interventions specifically targeting PA. For this subset of children with PA, pharmacotherapy may be an appropriate treatment option to optimize their functioning. This article reviews pharmacological treatment studies for PA in children and the safety and efficacy of risperidone, olanzapine, lithium, divalproex sodium, methylphenidate, and typical antipsychotics in this patient population. While safety needs to be emphasized when prescribing medication for these patients, serious health and safety risks are also raised when PA is not effectively treated. Future research is needed to evaluate whether the long-term risks associated with the pharmacological treatment of PA outweigh the potential benefits to the child.


  • A Retrospective Chart Review of Intramuscular Ziprasidone for Agitation in Children and Adolescents on Psychiatric Units: Prospective Studies Are Needed

    by Drew H. Barzman, Melissa P. DelBello, Jacob J. Forrester, Paul E. Keck, Stephen M. Strakowski

    Our primary objective was to evaluate the effectiveness and tolerability of intramuscular ziprasidone for impulsivity and agitation in psychiatrically hospitalized children and adolescents. Our secondary objective was to examine demographic and clinical factors associated with treatment response. We conducted a retrospective chart review of children and adolescents admitted to Cincinnati Children's Hospital Medical Center (CCHMC) psychiatric units between January 1, 2002, and July 11, 2005, who received intramuscular ziprasidone. Medical records were reviewed to determine demographic and clinical information as well as tolerability and effectiveness of ziprasidone. The Behavioral Activity Rating Scale (BARS) was used retrospectively to assess clinical response. Regression analyses were performed to evaluate the effect of demographic factors (age, gender, and ethnicity) and primary psychiatric diagnoses on treatment response. Electrocardiogram (ECG) data was inadequate. Fifty nine children and adolescents received a total of 77 injections of intramuscular ziprasidone for acute agitation. The mean +/- SD BARS score decreased from 6.5 +/- 0.7 to 3.1 +/- 1.3. The most common side effect was drowsiness or falling asleep (n = 46, 60%). Three (4%) could not be roused after the injection. Intramuscular ziprasidone may be helpful for agitation but often caused oversedation. Safety data, including ECGs, is needed in controlled prospective studies.


  • Rates, types, and psychosocial correlates of legal charges in adolescents with newly diagnosed bipolar disorder

    by Drew H Barzman, Melissa P DelBello, David E Fleck, Heather Lehmkuhl, Stephen M Strakowski

    Objectives:  To examine the rates, types, and psychosocial correlates of legal charges in adolescents with newly diagnosed bipolar disorder (BD).Methods:  Adolescents (n = 80), between the ages of 12 and 21 years (mean = 15.6, standard deviation = 2.3), hospitalized for their initial manic or mixed episode of BD, were evaluated for the incidence of prior juvenile offending (i.e., legal charges). We examined potential psychosocial correlates associated with legal charges using chi‐square, t‐tests, and discriminant function analyses to determine if there were differences between adolescents who did and did not offend prior to their first manic episode.Results:  Juvenile antisocial behaviors were common (55%) for adolescents with newly diagnosed BD. Discriminant function analysis revealed that older age at first treatment (p < 0.01), sexual activity over the previous month (p < 0.05), therapeutic use of stimulants (p < 0.05), and anxiety disorders were the most significant factors to differentiate between bipolar adolescents who offended and those who did not (Wilks’ lambda = 0.80, p < 0.005).Conclusions:  Our findings indicate that there are identifiable psychosocial correlates associated with antisocial behaviors in adolescents with newly diagnosed BD that may improve our understanding of juvenile antisocial behaviors.


  • The Efficacy and Tolerability of Quetiapine versus Divalproex for the Treatment of Impulsivity and Reactive Aggression in Adolescents with Co-Occurring Bipolar Disorder and Disruptive Behavior Disorder(s)

    by Drew H. Barzman, Melissa P. DelBello, Caleb M. Adler, Kevin E. Stanford, Stephen M. Strakowski

    Objective: The aim of this study was to compare the efficacy and tolerability of quetiapine and divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorders. Method: Patients were included in this post hoc analysis if they scored ≥14 on the Positive and Negative Syndrome Scale (PANSS) Excited Component (EC) and ≥4 on at least one of the PANSS EC items, had a current diagnosis of bipolar I disorder, manic or mixed episode, and had a lifetime and/or current diagnosis of a disruptive behavioral disorder (DBD) [conduct disorder (CD) or oppositional defiant disorder (ODD)]. Thirty-three (92%) of the 36 subjects with bipolar disorder and DBD met the PANSS EC inclusion criteria. These thirty-three adolescents were randomized to quetiapine (400–600 mg/day) or divalproex (serum level 80–120 µg/mL) for 28 days in this double-blinded study. The primary efficacy measure was change in PANSS Excited Component (EC) score over the study period and at each time point. Results: Repeated measures analysis of variance (ANOVA) demonstrated statistically significant within-treatment-group effects for divalproex (baseline = 20.6, end point = 13.3, p < 0.0001) and quetiapine (baseline = 18.8, end point = 10.8, p < 0.0001) for the PANSS EC. There were no statistically significant treatment group differences in PANSS EC changes from baseline to end point scores (p = 0.7, d = 0.14). Mixed regression analyses (comparison of slopes, DAY*TREATMENT) revealed that there was no significant difference in the rate of improvement in the PANSS EC scores between the two treatment groups [F(1,31) = 0.78, p = 0.39, d = 0.28]. Conclusions: Quetiapine and divalproex showed similar efficacy for the treatment of impulsivity and reactive aggression related to co-occurring bipolar and disruptive behavior disorders in adolescents. Quetiapine and divalproex are both useful as monotherapy for the treatment of impulsivity and reactive aggression in adolescents with bipolar and disruptive behavior disorders. Placebo-controlled studies are necessary.


  • Impulsive aggression with irritability and responsive to divalproex: A pediatric bipolar spectrum disorder phenotype?

    by Drew H. Barzman, Brian J. McConville, Brian Masterson, Susan McElroy, Gopalan Sethuraman, Krissell Moore, Ann-Marie Kahwaty, Daniel Nelson


  • The Effectiveness and Tolerability of Aripiprazole for Pediatric Bipolar Disorders: A Retrospective Chart Review

    by Drew H. Barzman, Melissa P. DelBello, Robert A. Kowatch, Beth Gernert, David E. Fleck, Sanjeev Pathak, Katherine Rappaport, Sergio V. Delgado, Pamela Campbell, Stephen M. Strakowski

    Objective: The aim of this retrospective chart review was to evaluate the effectiveness and tolerability of aripiprazole for the treatment of children and adolescents with bipolar disorders. Methods: The medical charts of all children and adolescents with a DSM-IV diagnosis of bipolar disorder, type I, type II, not otherwise specified (NOS), or schizoaffective disorder, bipolar type, and who were treated with aripiprazole were reviewed by two child and adolescent psychiatrists who independently confirmed their DSM-IV diagnoses, severity, and the improvement of illness using the Clinical Global Impression (CGI) Severity and Improvement scores for bipolar disorder (CGI-BP) and the Clinical Global Assessment Scale (CGAS). Results: Thirty patients who were treated with aripiprazole were identified (mean starting dose = 9 ± 4 mg/day, mean final dose = 10 ± 3 mg/day). The overall response rate, defined by a CGI—Improvement score of ≤ 2 at endpoint, was 67%. There was a statistically significant improvement in CGAS scores (48 ± 11 to 65 ± 11, signed rank = 191, p < 0.0001) and CGI-S scores (4.2 ± 0.8 to 2.8 ± 1.0, signed rank = –172, p < 0.0001, effect size = 1.90) from baseline to endpoint. No serious adverse events were identified. Common side effects were sedation (n = 10, 33%), akathisia (n = 7, 23%), and gastrointestinal disturbances (n = 2, 7%). Baseline and endpoint weights were available for 14 (47%) of the patients. Change in weight ranged from +5 to -21 kg and 12 (86%) of 14 patients lost weight (mean weight loss was 3 ± 6 kg). Conclusions: This retrospective chart review suggests that aripiprazole may be effective and well tolerated for children and adolescents with bipolar disorders. Controlled studies of aripiprazole for the treatment of pediatric bipolar disorder are necessary.